Trevi Therapeutics announced that on March 7 the USPTO issued a notice of allowance for nalbuphine ER’s method of treatment of chronic cough in IPF. Trevi expects the resulting patent will be Orange Book-listable with an anticipated expiration in 2039. Trevi intends to continue to prosecute additional patent applications to further enhance its existing patent estate protecting nalbuphine ER across multiple chronic cough conditions as additional clinical data is generated.
Published first on TheFly